Skip to content
Bored Studies
Recruiting

Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference

Capso Vision, Inc. · NCT07089615

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 45–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
330
US sites recruiting
11
Study start
June 26, 2025
Record last updated
May 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied.

The purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference.

The participant will

  • prep for and swallow a study capsule and then
  • prep for and undergo a colonoscopy either the following day or 3-6 weeks later

Being studied: Capsule swallow

Conditions: Colonic Polyps

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 45-75 years of age
  • Committed to undergo a colonoscopy.
  • Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor

Exclusion Criteria

  • Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps
  • Has contraindication for capsule endoscopy or colonoscopy
  • Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome
  • Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease
  • History of incomplete colonoscopy
  • Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C>6.4 within the past 3 months and/or with history of constipation or gastroparesis).
  • Impaired cardiac function assessed as greater than NYHA Class II
  • History of small- or large-bowel obstructive condition
  • Known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis
  • Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention
  • Known allergy to ingredients used in bowel preparation and boosters
  • Daily and/or regular narcotic use
  • Decompensated cirrhosis
  • Prior abdominal radiation therapy
  • Diagnosis of anorexia or bulimia
  • History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation
  • Known or suspected megacolon
  • Scheduled to undergo MRI examination within 7 days after ingestion of the capsule
  • Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis
  • Pregnant or nursing or of child-bearing potential and does not agree to practice medically acceptable methods of contraception. Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at screening.
  • Unable to follow or tolerate fasting, bowel preparation, and other study procedures
  • Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results
  • Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study
  • Chronic constipation as defined by \<3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements

Recruiting US locations

  • SB Gastro Clinical Research

    Chula Vista, CA 91910

    Site contact: Study Coordinator · 619-513-3372 · judy@gastrosb.com

  • Gastro Care Institute

    Lancaster, CA 93534

    Site contact: Lead Study Coordinator · 661-529-7550 · Rvargas@gciav.com

  • Knowledge Research Center

    Orange, CA 92868

    Site contact: Regulatory/Study Coordinator · 657-247-0087 · j.bermudez@knowledgeresearchcenter.com

  • Advanced Research Institute

    St. Petersburg, FL 33710

    Site contact: Study Coordinator · 727-835-3261 · lauren.scott@ariclinical.com

  • Digestive Health Services

    Downers Grove, IL 60515

    Site contact: Site Manager · (708) 253-5810 · devang.shah@avicennaclinical.com

  • Gastroenterology and Internal Medicine Specialists

    Lake Barrington, IL 60010

    Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com

  • Northshore Center for Gastroenterology

    Libertyville, IL 60048

    Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com

  • Suburban Gastroenterology

    Naperville, IL 60540

    Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com

  • Southwest Gastroenterology

    Oak Lawn, IL 60453

    Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com

  • Gastroenterology Group of Rochester

    Rochester, NY 14618

    Site contact: Lead Study Coordinator · 585-278-1116 · bvasciannie@ggr1.com

  • Great Lakes Gastroenterology Research

    Mentor, OH 44060

    Site contact: Lead Clinical Research Coordinator · 216-387-4966 · susand@greatlakesgastro.net

Study contacts (from the official record)

  • Taylor Williamsen Principle CRA/Study Lead · 815-861-9575 · taylor.williamsen@capsovision.com
  • Rebecca Petersen Sr. Director of Clinical Affairs · 510-566-8824 · rebecca.petersen@capsovision.com
Prospective, Open-label, Non-significant Risk, Multicenter Study… (NCT07089615) | Bored Studies